Apotex founder found dead at home
Apotex, the world’s seventh largest generics manufacturer, has lost its Chairman and founder, after Barry Sherman and his wife, Honey, were found dead at their house in Toronto, Canada. The exact cause of their deaths is still being investigated.
The deaths are currently being treated as suspicious, with numerous reports suggesting that the bodies of the two individuals were found hanging from a railing.
The couple were prominent figures in Canadian society, leading to speculation as to what the circumstances of their deaths were. The family of the couple reacted with a statement to media reports that suggested it could have been a murder-suicide scenario.
“Our parents shared an enthusiasm for life and commitment to their family and community totally inconsistent with the rumours regrettably circulated in the media as to the circumstances surrounding their deaths.
“We are shocked and think it’s irresponsible that police sources have reportedly advised the media of a theory which neither their family, their friends nor their colleagues believe to be true.
“We urge the Toronto Police Service to conduct a thorough, intensive and objective criminal investigation, and urge the media to refrain from further reporting as to the cause of these tragic deaths until the investigation is completed.”
Barry Sherman founded Apotex in 1974, establishing the company from a small 5,000 square-feet facility to a company that employed more than 11,000 people.
The growth of the company had led to it reap annual sales of more than C$2 billion and bases in 45 countries. Sherman stepped down from the Chief Executive role in 2012 but remain at the company as Executive Chairman.
Barry Sherman’s success with Apotex had led him to accrue a wealth of $3.7 billion, according to Canadian Business. The couple were noted for their philanthropic endeavours and Honey Sherman had been awarded a Canadian senate medal for community service. They leave behind four children.
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …